The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.

Zhimeng Biopharma enrolls 255 patients in ALS Phase 2/3 trial

Oct 31, 2026 05:00 (9h ago)

Verifying

Zhimeng Biopharma completed enrollment for its pivotal CB03-154 ALS trial.
The Phase 2/3 study enrolled 255 patients across 15 Chinese research centers.
Zhimeng plans a conditional-approval application if third-quarter 2027 Phase 2 results are positive.